Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021
During January-August 2021, the Community Prevalence of SARS-CoV-2 Study used time/location sampling to recruit a cross-sectional, population-based cohort to estimate SARS-CoV-2 seroprevalence and nasal swab sample PCR positivity across 15 US communities. Survey-weighted estimates of SARS-CoV-2 infection and vaccine willingness among participants at each site were compared within demographic groups by using linear regression models with inverse variance weighting. Among 22,284 persons >2 months of age and older, median prevalence of infection (prior, active, or both) was 12.9% across sites and similar across age groups. Within each site, average prevalence of infection was 3 percentage points higher for Black than White persons and average vaccine willingness was 10 percentage points lower for Black than White persons and 7 percentage points lower for Black persons than for persons in other racial groups. The higher prevalence of SARS-CoV-2 infection among groups with lower vaccine willingness highlights the disparate effect of COVID-19 and its complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 30(2024), 2 vom: 02. Feb., Seite 245-254 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 02.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid3002.230863 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367605511 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367605511 | ||
| 003 | DE-627 | ||
| 005 | 20240202232200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid3002.230863 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367605511 | ||
| 035 | |a (NLM)38270128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Justman, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a During January-August 2021, the Community Prevalence of SARS-CoV-2 Study used time/location sampling to recruit a cross-sectional, population-based cohort to estimate SARS-CoV-2 seroprevalence and nasal swab sample PCR positivity across 15 US communities. Survey-weighted estimates of SARS-CoV-2 infection and vaccine willingness among participants at each site were compared within demographic groups by using linear regression models with inverse variance weighting. Among 22,284 persons >2 months of age and older, median prevalence of infection (prior, active, or both) was 12.9% across sites and similar across age groups. Within each site, average prevalence of infection was 3 percentage points higher for Black than White persons and average vaccine willingness was 10 percentage points lower for Black than White persons and 7 percentage points lower for Black persons than for persons in other racial groups. The higher prevalence of SARS-CoV-2 infection among groups with lower vaccine willingness highlights the disparate effect of COVID-19 and its complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2019 novel coronavirus disease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a United States | |
| 650 | 4 | |a community surveys | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a surveys and questionnaires | |
| 650 | 4 | |a time/location sampling | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Skalland, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Ayana |e verfasserin |4 aut | |
| 700 | 1 | |a Amos, Christopher I |e verfasserin |4 aut | |
| 700 | 1 | |a Marzinke, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Zangeneh, Sahar Z |e verfasserin |4 aut | |
| 700 | 1 | |a Kelley, Colleen F |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Stockton |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch-Moverman, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Doblecki-Lewis, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Metzger, David |e verfasserin |4 aut | |
| 700 | 1 | |a Barranco, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, Ernesto T A |e verfasserin |4 aut | |
| 700 | 1 | |a Powers-Fletcher, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Kissinger, Patricia J |e verfasserin |4 aut | |
| 700 | 1 | |a Farley, Jason E |e verfasserin |4 aut | |
| 700 | 1 | |a Knowlton, Carrie |e verfasserin |4 aut | |
| 700 | 1 | |a Sobieszczyk, Magdalena E |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminathan, Shobha |e verfasserin |4 aut | |
| 700 | 1 | |a Reed, Domonique |e verfasserin |4 aut | |
| 700 | 1 | |a Tapsoba, Jean De Dieu |e verfasserin |4 aut | |
| 700 | 1 | |a Emel, Lynda |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Yuhas, Krista |e verfasserin |4 aut | |
| 700 | 1 | |a Schrumpf, Leah |e verfasserin |4 aut | |
| 700 | 1 | |a Mkumba, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Jontraye |e verfasserin |4 aut | |
| 700 | 1 | |a Lucas, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Piwowar-Manning, Estelle |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Shahnaz |e verfasserin |4 aut | |
| 700 | 0 | |a CoVPN 5002 COMPASS Study Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 30(2024), 2 vom: 02. Feb., Seite 245-254 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:02 |g month:02 |g pages:245-254 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid3002.230863 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 02 |c 02 |h 245-254 | ||